-

Benson Hill Announces Second Quarter Earnings Release Date

ST. LOUIS--(BUSINESS WIRE)--Benson Hill, Inc. (NYSE: BHIL, the “Company” or “Benson Hill”), a food tech company unlocking the natural genetic diversity of plants, announced today that it will release its financial results for the second quarter ending June 30, 2023, before the market opens on Wednesday, Aug. 9, 2023.

The Company will host a webcast to discuss the results at 8:30 a.m. Eastern Time, including a presentation by management followed by a Q&A session. The Aug. 9 webcast will be accessible via a link on Benson Hill’s investor relations website at https://investors.bensonhill.com.

About Benson Hill

Benson Hill moves food forward with the CropOS® platform, a cutting-edge food innovation engine that combines data science and machine learning with biology and genetics. Benson Hill empowers innovators to unlock nature’s genetic diversity from plant to plate, with the purpose of creating nutritious, great-tasting food and ingredient options that are both widely accessible and sustainable. More information can be found at bensonhill.com or on Twitter at @bensonhillinc.

Contacts

Investor Contact
Benson Hill
Ruben Mella
314-714-6313
rmella@bensonhill.com

Media Contact
Benson Hill
Christi Dixon
636-359-0797
cdixon@bensonhill.com
Media Kit

Benson Hill, Inc.

NYSE:BHIL

Release Summary
Benson Hill announced today that it will release its financial results for the second quarter before the market opens on Wednesday, Aug. 9, 2023.
Release Versions
$Cashtags

Contacts

Investor Contact
Benson Hill
Ruben Mella
314-714-6313
rmella@bensonhill.com

Media Contact
Benson Hill
Christi Dixon
636-359-0797
cdixon@bensonhill.com
Media Kit

Social Media Profiles
More News From Benson Hill, Inc.

Confluence Genetics Launches Cas-CLEAR™, a New CRISPR Technology Platform for Cancer Therapy

ST. LOUIS--(BUSINESS WIRE)--Confluence Genetics today announced the launch of Cas-CLEAR™, Collaterally Enhanced Activated Ribonuclease, a new CRISPR technology platform for the treatment of cancers carrying defined genetic signatures, with lead programs in development for hepatocellular carcinoma (HCC). Unlike gene editing CRISPR systems that cut and modify DNA at a single site, Cas-CLEAR uses Cas12a2 nucleases to recognize cancer-specific genetic signatures and trigger broad collateral cleavag...

Confluence Genetics Partners With Ag Partners Cooperative to Increase Commercial Acres of ProVIA™ Soybeans Following Successful Broiler Performance Trials

ST. LOUIS--(BUSINESS WIRE)--Confluence Genetics, LLC. has received positive results from a second collaborative feeding trial with a major poultry integrator, validating the consistent performance benefits of soybean meal derived from the Company's Ultra-High Protein, Low Oligosaccharide (UHP-LO) ProVIA™ soybeans. The 42-day broiler trial replicated results from an initial study with the same integrator, demonstrating that UHP-LO soybean meal can reliably improve broiler performance while reduc...

Confluence Genetics Ultra-High Protein Low Oligosaccharide Soybeans Demonstrate Superior Performance in a Large-Scale Turkey Feeding Trial

ST. LOUIS--(BUSINESS WIRE)--Confluence Genetics, LLC, a leading seed innovation company, today announced positive results from a comprehensive 20-week turkey feeding trial conducted in collaboration with a large poultry integrator. The study validates the commercial advantages of soybean meal made from Confluence Genetics' ProVIA™ Ultra-High Protein, Low Oligosaccharide (UHP-LO) soybeans as a complete replacement for conventional soybean meal in turkey diet formulations. The large-scale trial i...
Back to Newsroom